These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 15994763)
21. Broad-spectrum inhibitor of viruses in the Flaviviridae family. Ojwang JO; Ali S; Smee DF; Morrey JD; Shimasaki CD; Sidwell RW Antiviral Res; 2005 Nov; 68(2):49-55. PubMed ID: 16199098 [TBL] [Abstract][Full Text] [Related]
22. Novel approaches to flavivirus drug discovery. Botting C; Kuhn RJ Expert Opin Drug Discov; 2012 May; 7(5):417-28. PubMed ID: 22439769 [TBL] [Abstract][Full Text] [Related]
23. Ten years of dengue drug discovery: progress and prospects. Lim SP; Wang QY; Noble CG; Chen YL; Dong H; Zou B; Yokokawa F; Nilar S; Smith P; Beer D; Lescar J; Shi PY Antiviral Res; 2013 Nov; 100(2):500-19. PubMed ID: 24076358 [TBL] [Abstract][Full Text] [Related]
24. Crotoxin and phospholipases A₂ from Crotalus durissus terrificus showed antiviral activity against dengue and yellow fever viruses. Muller VD; Russo RR; Cintra AC; Sartim MA; Alves-Paiva Rde M; Figueiredo LT; Sampaio SV; Aquino VH Toxicon; 2012 Mar; 59(4):507-15. PubMed ID: 21723310 [TBL] [Abstract][Full Text] [Related]
25. [Antiviral strategies. Dengue and West Nile Virus]. Klein C Pharm Unserer Zeit; 2010; 39(1):50-3. PubMed ID: 20033943 [No Abstract] [Full Text] [Related]
26. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029 [TBL] [Abstract][Full Text] [Related]
27. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. Schul W; Liu W; Xu HY; Flamand M; Vasudevan SG J Infect Dis; 2007 Mar; 195(5):665-74. PubMed ID: 17262707 [TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases. Lai H; Dou D; Aravapalli S; Teramoto T; Lushington GH; Mwania TM; Alliston KR; Eichhorn DM; Padmanabhan R; Groutas WC Bioorg Med Chem; 2013 Jan; 21(1):102-13. PubMed ID: 23211969 [TBL] [Abstract][Full Text] [Related]
29. A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity. Moshiri J; Constant DA; Liu B; Mateo R; Kearnes S; Novick P; Prasad R; Nagamine C; Pande V; Kirkegaard K mBio; 2020 Nov; 11(6):. PubMed ID: 33173007 [TBL] [Abstract][Full Text] [Related]
30. Development and characterization of mouse monoclonal antibodies against monomeric dengue virus non-structural glycoprotein 1 (NS1). Gelanew T; Poole-Smith BK; Hunsperger E J Virol Methods; 2015 Sep; 222():214-23. PubMed ID: 26070890 [TBL] [Abstract][Full Text] [Related]
31. An iminosugar with potent inhibition of dengue virus infection in vivo. Perry ST; Buck MD; Plummer EM; Penmasta RA; Batra H; Stavale EJ; Warfield KL; Dwek RA; Butters TD; Alonzi DS; Lada SM; King K; Klose B; Ramstedt U; Shresta S Antiviral Res; 2013 Apr; 98(1):35-43. PubMed ID: 23376501 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of dengue antiviral candidates in vivo in mouse model. Watanabe S; Vasudevan SG Methods Mol Biol; 2014; 1138():391-400. PubMed ID: 24696350 [TBL] [Abstract][Full Text] [Related]
33. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Ganesh VK; Muller N; Judge K; Luan CH; Padmanabhan R; Murthy KH Bioorg Med Chem; 2005 Jan; 13(1):257-64. PubMed ID: 15582469 [TBL] [Abstract][Full Text] [Related]
34. Murine Efficacy and Pharmacokinetic Evaluation of the Flaviviral NS5 Capping Enzyme 2-Thioxothiazolidin-4-One Inhibitor BG-323. Bullard KM; Gullberg RC; Soltani E; Steel JJ; Geiss BJ; Keenan SM PLoS One; 2015; 10(6):e0130083. PubMed ID: 26075394 [TBL] [Abstract][Full Text] [Related]
35. Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy. Watanabe S; Chan KW; Dow G; Ooi EE; Low JG; Vasudevan SG Antiviral Res; 2016 Mar; 127():10-9. PubMed ID: 26794905 [TBL] [Abstract][Full Text] [Related]
36. Discovery of host-targeted covalent inhibitors of dengue virus. de Wispelaere M; Carocci M; Liang Y; Liu Q; Sun E; Vetter ML; Wang J; Gray NS; Yang PL Antiviral Res; 2017 Mar; 139():171-179. PubMed ID: 28034743 [TBL] [Abstract][Full Text] [Related]
37. Targeting host factors to treat West Nile and dengue viral infections. Krishnan MN; Garcia-Blanco MA Viruses; 2014 Feb; 6(2):683-708. PubMed ID: 24517970 [TBL] [Abstract][Full Text] [Related]
38. [Search for inhibitors of West Nile virus among antibiotics]. Azarova IA; Mishaeva NP; Votiakov VI; Golovneva GP Antibiot Khimioter; 1992 Aug; 37(8):29-31. PubMed ID: 1456820 [TBL] [Abstract][Full Text] [Related]
39. Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients. Sung C; Wei Y; Watanabe S; Lee HS; Khoo YM; Fan L; Rathore AP; Chan KW; Choy MM; Kamaraj US; Sessions OM; Aw P; de Sessions PF; Lee B; Connolly JE; Hibberd ML; Vijaykrishna D; Wijaya L; Ooi EE; Low JG; Vasudevan SG PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004851. PubMed ID: 27509020 [TBL] [Abstract][Full Text] [Related]
40. In vitro antiviral activities of extracts derived from Daucus maritimus seeds. Miladi S; Abid N; Debarnôt C; Damak M; Canard B; Aouni M; Selmi B Nat Prod Res; 2012; 26(11):1027-32. PubMed ID: 21895456 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]